Advagraf

Phase 3

Astellas Pharma (ALPMY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Heart Transplantation

View Full Landscape

Drug Information

Target Indication

Heart Transplantation

Clinical Trial

NCT01332201

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/23/2007

Advagraf

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

micafungin (Mycamine)Phase 3

Fungemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts